Alpha Cognition Inc. announced the pricing of its oversubscribed underwritten public offering of 5,600,000 common shares at $6.25 per share, generating gross proceeds of $35.0 million. The offering was led by a premier healthcare-dedicated investor and included multiple large existing shareholders.
The company granted the underwriter a 30-day option to purchase up to an additional 840,000 common shares to cover over-allotments. Following the closing, Alpha Cognition's total cash position is expected to be approximately $70 million.
The net proceeds from this offering are earmarked for accelerating the commercial launch of ZUNVEYL, with a focus on sales expansion, increased marketing investment, and enhancing payer coverage and reimbursement infrastructure. These investments are designed to maximize near-term adoption and establish a sustainable commercial presence in the Alzheimer’s treatment landscape.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.